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ABSTRACT 
Background: Resistant ulcerative proctitis can be extremely difficult to manage. Topically 
administered tacrolimus, however, may be effective in difficult-to-treat proctitis.  
Aims: This was randomized, double-blind, placebo-controlled induction trial of rectal tacrolimus in 
patients with active ulcerative colitis. 
Methods: Eleven patients received rectal tacrolimus (0.5mg/ml), and 10 placebo, for 8 weeks. The 
primary endpoint was clinical response by using the Mayo clinic score. 
Results: A planned interim analysis after 20 patients had completed the study demonstrated highly 
significant differences between the groups and the study was closed due to ethical considerations 
with patients already recruited allowed to complete the study. The primary endpoint was met in 
8/11 patients receiving rectal tacrolimus and 1/10 patients receiving placebo (73% vs. 10%; 
p=0.004). Of the secondary endpoints, 5 rectal tacrolimus patients achieved clinical remission 
compared to none receiving placebo (45% vs. 0%; p=0.015). Mucosal healing at week 8 was 
achieved in 8 patients receiving rectal tacrolimus compared to 1 (73% vs.10%) receiving placebo 
(p=0.004). The IBDQ increased ≥16 points over baseline in 5 of the tacrolimus and 2 (45% vs. 
20%) of the placebo patients (p=0.36). Finally, the average partial Mayo score was numerically 
lower in the tacrolimus-treated group compared to placebo at week 2 (4.3±0.74 vs. 5.8±0.64; 
p=0.15) and week 4 (3.7±0.96 vs. 5.8±0.6; p=0.08) but was significantly lower at week 8 (3.3±1.2 
vs. 6.7±0.62; p=0.01). There were no safety issues identified with rectal tacrolimus use. 
Conclusion: Rectal tacrolimus was more effective than placebo for induction of a clinical response, 
clinical remission and mucosal healing in resistant ulcerative proctitis (Clinicaltrials.gov 
registration: NCT01418131) 
 
Key Words; Ulcerative colitis, proctitis, tacrolimus, blinded randomised clinical trial 
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INTRODUCTION 
Ulcerative Colitis (UC) is thought to result from an interaction between both environmental and 
genetic factors with disease activity characterised by a life-long course of remissions and 
exacerbations, however, approximately 20-55% of UC patients will suffer, at some stage, a severe 
attack requiring hospitalisation1. The Montreal classification2 divides the distribution of UC into 
ulcerative proctitis - E1 (limited to the rectum), left-sided colitis - E2 (up to the splenic flexure) and 
extensive colitis  - E3 (beyond splenic flexure).   
 
Inflammation confined to the rectum (E1) occurs in approximately 25% of UC patients and 
although this results in distressing symptoms, including stool frequency, tenesmus (a feeling of 
incomplete evacuation), faecal urgency and bleeding, it can often be managed within the 
community with topical agents3. Medication-resistant ulcerative proctitis, however, can be 
extremely challenging to manage. When rectal medications fail, oral agents including the 5-
aminosalicylic acids (5-ASAs), azathioprine ⁄ 6-mercaptopurine (AZA ⁄ 6MP) and steroids may be 
employed, but they do not always help. The anti-tumour necrotic factor (TNF)α medications may 
also be an effective treatment and can have a response rate of 68% and a remission rate of 40% by 2 
weeks4, while the recent inclusion of the new anti-intergin therapy, vedolizumab, on many 
formularies has offered another potentially effective option5, 6. These biological therapies, however, 
are still not universally effective, are systemic and carry a considerable cost burden. 
 
Tacrolimus and cyclosporin are classical calcineurin inhibitors and are widely used as 
immunosuppressive medications and have demonstrated promising results in the management of 
UC7, 8. Calcineurin, or protein phosphatase 2B (PP2B), is a ubiquitously expressed cytosolic 
Ser/Thr protein phosphatase, that is highly conserved in eukaryotes9. It has the ability to 
dephosphorylate a broad range of proteins and can regulate interleukin (IL)-2, IL-4 and interferon 
(IFN)γ expression10, as well as modulating the activity of transcription factors like NF-κB11. 
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Enhanced NF-kB activity is well described in CD and UC and induces the proinflammatory 
cytokine IL-1β, IL-6 and TNFα expression. It is primarily through the reduction in the levels of 
these cytokines that clinical remission is thought to be achieved. 
 
The efficacy of oral tacrolimus has been examined in the management of medication-resistant CD 
and UC. Unfortunately, the majority of these studies have been open-labelled with only one 
randomised-controlled trial reported in UC12. This demonstrated a short-term clinical improvement 
but without a significant increase in remission, potentially due to low patient numbers. Despite this, 
there are numerous open-labelled studies in both UC and CD that suggest efficacy in the short-term, 
and with promising long-term data13-18. The evidence would suggest, however, that the blood trough 
levels should be at least 10ug/L in order to achieve the best efficacy (therapeutic range 5-20ug/L), 
but the higher the trough level the more likely a patient will suffer an adverse effect19. These, 
unfortunately, can be numerous and include hypertension, nausea and diarrhoea, haematological 
abnormalities, renal impairment13. Increase in the rate of skin cancers is also a concern20, a side 
effect that has been supported by animal studies21.  
 
Use of topical tacrolimus has been effective in the treatment of perioral and perineal inflammation 
in paediatric CD patients with resolution of symptoms in 75%22. Work examining topical perianal 
tacrolimus therapy in adult CD patients also demonstrated clinical efficacy23, and although 
tacrolimus is absorbed well transdermally24, only low trough levels of tacrolimus were detected in 
the blood23. In these preliminary studies, the use of topical tacrolimus was associated with very few 
side effects. Long-term topical use, as with oral formulations, may be associated with an increased 
risk of skin cancer formation. Epidemiological evidence, however, would suggest that the risk is 
low and localised only to the tacrolimus-treated sun-exposed skin25-27.  
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A pilot study by our group demonstrated that 75% (6/8) of patients with resistant distal colitis 
responded and achieved a clinical remission of their disease following 4 to 8 weeks of tacrolimus 
rectal ointment28. A dose of 0.3 to 0.5mg/ml 3ml twice a day was identified in the majority of 
patients to induce remission. In these patients, tacrolimus trough levels were taken regularly and 
were either undetectable (<1.5ug/L), sub-therapeutic (<5ug/L) or, at their highest, in the low 
therapeutic range (therapeutic range 5-20ug/L). The ointment was well tolerated without any 
systemic adverse effects. Use of the same rectal tacrolimus preparation in more than another 20 
patients by the chief investigator has also been associated with a clinical response in up to 75% 
patients following 4 weeks of therapy. The efficacy of topical tacrolimus in UC is further supported 
by a separate pilot study that examined topical tacrolimus in patients with resistant distal colitis. In 
this study clinical and histological improvement was achieved in 10 of 12 patients with proctitis by 
4 weeks. Again no major side effects were reported and the preparation was well tolerated29. The 
mechanism of action of tacrolimus would also appear to be local, rather than systemic, immune 
suppression as the administration of rectal tacrolimus inhibits the activation of immune cells within 
the intestinal mucosa and not systemically30. Thus as the studies, and observations, demonstrate 
encouraging results in a difficult-to-treat patient population, a randomised double-blinded placebo-
controlled trial was warranted. 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
MATERIALS AND METHODS 
Study Design 
This was randomised, double-blind, placebo-controlled UC induction study conducted at 4 
specialist IBD centers in Australia. (Fremantle Hospital, WA; Royal Brisbane and Women’s 
Hospital, Qld; Royal Adelaide Hospital, SA; and Liverpool Hospital, NSW) The protocol was 
approved by the Eli and Edythe Board foundation, which funded the work, and by each human 
ethics committee at each center. As the medication was not approved by the Therapeutic Goods 
Administration (TGA) in Australia, approval to use the medication in a clinical trial was obtained 
from the TGA for each participating site. All patients gave written informed consent. The study was 
conducted and reported in accordance with the protocol available at ClinicalTrials.com 
(registration: NCT01418131). 
 
Tacrolimus rectal ointment preparation: 
The preparation of the tacrolimus rectal ointment was undertaken in the hospital pharmacy of each 
of the participating sites. Gloves and mask were worn when making the preparation. The final 
concentration of tacrolimus in the rectal ointment was 0.5mg/ml28. To create the tacrolimus 
preparation, 5ml of propylene glycol was slowly mixed into the desired amount of tacrolimus 
powder on a clean glass slab.  To this 70 ml of paraffin liquid BP was gradually added by serial 
dilution and triturate until evenly mixed.  This process was repeated with 125ml of paraffin white 
soft BP.  The resulting cream was packed into tubes and labelled.  The cream is stable for over 30 
days when stored at room temperature and over 90 days if refrigerated. The preparation was 
formulated using the LP/WSP base for ease of rectal use. To create the placebo, the same process 
was followed but without the addition of the tacrolimus powder. A total of 3 ml of the 
tacrolimus/placebo ointment was applied rectally, via an applicator, twice a day by the patient over 
the 8-week period. Patients received their rectal preparation at the randomisation and the week 4 
visit  
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Study population: 
Eligible patients were 18 years, or older, and had a diagnosis of UC made in accordance with 
established international criteria based on clinical, endoscopic, histological and radiological 
features)2 of greater >3 months duration.  All patients had active inflammation defined as a Mayo 
score of 6-12 (range, 0 to 12, with higher scores indicating more active disease)31 that was limited 
to a maximum of 25cm from the anal verge. All patients had failed conventional therapies of either 
oral and/or rectal 5-aminosalicylates (5 ASAs) and/or oral and rectal steroids, or were intolerant of 
these medications. Patients on rectal preparations were allowed to continue their rectal medication 
up to the day prior to commencing the rectal tacrolimus trial. Patients taking oral 5-aminosalicylates 
had used them continuously for 4 weeks and were on a stable dose for 2 weeks prior to the 
screening visit, while patients on oral corticosteroids had used them continuously for 4 weeks and 
were on a stable dose of 30mg, or less, for 2 weeks prior to the screening visit. Patients on AZA / 
6MP or methotrexate (MTX) had used them for a minimum of 12 weeks with a stable dose for 4 
weeks prior to the screening visit. 
 
Patients were ineligible for this study if they had a known hypersensitivity/allergic reaction to 
rectal/oral tacrolimus, were pregnant or breast-feeding, or suffered from uncontrolled hypertension 
or chronic renal failure. Patients were also ineligible for the study if they had received an anti- 
TNFα medication, or any trial or biological agent, within 8 weeks of the screening visit. Other 
exclusion criteria included patients with drug abuse, alcohol dependence, dementia or an inability to 
understand the trial requirements, patients with colitis extending more than 25cm from the anal 
verge and patients who have previously been treated with a rectal tacrolimus preparation. Subjects 
were discontinued from the study if they revoked their consent, or at the discretion of the principal 
investigator, based on disease, side effects or poor compliance.  
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Screening and Baseline Studies: 
Assessments performed before randomisation included physical, blood tests and stool analysis for 
enteric pathogens.  Demographic data were collected. Eligible patients were scheduled for a visit 
within 7 days of randomisation, when a sigmoidoscopy was performed and baseline Mayo Clinic 
scores and scores on the Inflammatory Bowel Disease Questionnaire (IBDQ; range, 0 to 224, with 
normal Quality of life [QOL] defined as a score of ≥170 points with higher scores indicating a 
better QOL and a QOL response defined as a change of ≥16 points)32 were determined. 
 
Randomisation Procedures 
Patients were randomly assigned, in a 1:1 ratio, to receive either 0.5mg/ml 3ml twice a day of rectal 
tacrolimus or placebo for 8 weeks. Patients who did not respond by week 4 were allowed to 
withdraw and received open-label rectal tacrolimus. Randomisation was performed centrally with a 
computer-generated randomisation schedule. Permitted concomitant UC medications included 
aminosalicylates, glucocorticoids, and immunosuppressive agents that were continued at stable 
doses throughout the 8-week period. 
 
Follow-up 
Patients were seen at weeks 2, 4, and 8 during the study. The patient filled in a ‘Patient Diary Card’ 
with the date and time of administration of the rectal preparation. This diary card was checked for 
compliance by the investigators at each patient visit. At week 2 and 4, a partial Mayo score 
(consisting of the Mayo score minus the sigmoidoscopy subscore; range, 0 to 9, with higher scores 
indicating more active disease)33 was calculated. All adverse events were noted. IBDQ scores and 
blood samples for serum chemical, hematologic and tacrolimus trough level testing were obtained at 
each visit. Sigmoidoscopy was performed at week 8, or at study withdrawal if this was after at least 
4 weeks on the trial medication, and the full Mayo score calculated. 
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Outcomes 
The primary outcome was the clinical response (Mayo Score) at 8 weeks defined as a reduction in 
the Mayo Clinic score of ≥3 points and a decrease of >30% from the baseline score, with a decrease 
of ≥1 point on the rectal bleeding subscale or an absolute rectal bleeding score of 0 or 131. 
Secondary outcomes at week 8 were clinical remission, defined as a Mayo Clinic score of ≤2 and no 
subscore >1, and mucosal healing, defined as an endoscopic subscore of 0 or 131. Other secondary 
end points at 8 weeks were the effect of rectal tacrolimus on mucosal healing, changes in the partial 
Mayo Score33  and changes in the health-related QOL through the use of the IBDQ32. Safety and 
tolerability of rectal tacrolimus was assessed with adverse events classified with the use of the 
Medical Dictionary for Regulatory Activities 25 version 15. 
 
Study Oversight 
The study was designed and implemented by the chief investigator supported by a grant from the 
Broad Foundation. The study was monitored by the chief investigator’s site. Local investigators and 
their participating institutions agreed to maintain confidentiality of the data. The chief investigator 
wrote the manuscript with intellectual input obtained from each of the authors. All authors had 
access to the study data and reviewed and approved the final manuscript. All the authors made the 
decision to submit the manuscript for publication.  
 
Statistical analysis 
A sample size calculation determined that 20 patients per group was considered to be sufficient to 
see a difference between treatment and placebo group for the primary outcome measure with a 
significance level of 5% and power of 80%. Effects of time, treatment and the time by treatment 
interaction were tested and reported.  Estimated differences and 95% confidence intervals for 
differences are given for each time point. For all analyses the impact of potentially confounding 
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demographic variables such as sex and age were considered. Student T test, Chi squared and 
ANOVO analysis was undertaken with p values <0.05 considered significant. 
 
An interim analysis was written into the protocol and was to be undertaken by a blinded 
independent statistician and gastroenterological clinicians as detailed in the study design after 20 
patients had completed the 8-week study to determine safety and in order to determine that the 
study should continue. The study could be terminated at this point for either safety or ethical 
considerations. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
RESULTS 
Randomisation and Baseline Characteristics 
A total of 28 patients were assessed for inclusion into the study.  Of these 21 were enrolled and 
included for analysis. Seven patients did not meet the inclusion criteria of disease limited to the 
distal 25cm of the colon. In the trial, 11 patients were randomly assigned to receive tacrolimus 
0.5mg/ml twice a day and 10 were allocated to the placebo arm of the study. The baseline 
characteristics were similar between the placebo group and rectal tacrolimus group (Table 1). The 
Mayo endoscopy subscore at inclusion in the placebo group was 3 in 4 patients and 2 in 6 patients. 
The Mayo endoscopy subscore in the tacrolimus group was 3 in 6 patients and 2 in 5 patients. The 
mean Mayo score at week 0 in the tacrolimus group was 8.6±0.4 compared to 9.6±0.5 (p=0.11). 
There were also no significant differences observed between the groups in the other demographic or 
baseline characteristics nor in medication history between the groups. 
 
In the placebo group, 60% of patients had failed oral steroids, 30% topical steroids, 90% oral 
5ASAs and 50% an immunomodulator medication. In the tacrolimus group 64% of patients had 
failed oral steroids, 36% topical steroids, 73% oral 5ASAs and 64% an immunomodulator 
medication. All had failed topical 5ASA treatment. No patient in either group had been treated with 
an anti-integrin and only on patient in the tsacrolimus group had failed an anti-TNF medication. 
 
Outcomes 
An interim analysis was undertaken, as per the protocol, after 20 patients had completed the 8-week 
study. Due to the highly significant differences identified between the groups, across multiple 
endpoints, it was decided that ethically the study should be closed with any patients already 
commenced on the study allowed to complete the study.  No safety issues were identified. 
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A total of 21 patients completed the study. Two of the placebo patients and one rectal tacrolimus 
patient withdrew after the week 4 visit (2 at week 6 and 1 at week 4), as allowed by the protocol, 2 
due to perceived lack of efficacy and one due to pregnancy. These patients underwent a 
sigmoidoscopy examination and were included for analysis of the primary and secondary outcomes 
as per the protocol.  
 
The primary endpoint was met, in 8 of the 11 patients receiving rectal tacrolimus and 1 of the 10 
patients receiving placebo by having a clinical response (73% vs. 10%; p=0.004) at week 8 (Figure 
1). The mean Mayo score at week 8 in the tacrolimus group was 4.5±1.3 compared to 8.8±0.8 
(p=0.01; Figure 2). 
 
Of the secondary endpoints, 5 of the patients receiving rectal tacrolimus achieved clinical 
remission, whilst none of the patients receiving placebo achieved remission (45% vs. 0%; p=0.015). 
Mucosal healing at week 8 was achieved in 8 of patients receiving rectal tacrolimus compared to 1 
patients receiving placebo (73% vs. 10%; p=0.004). The IBDQ was ≥170 points (normal range) at 
baseline in one patient randomised to receive rectal tacrolimus and 3 (9% vs. 30%) of patients 
randomised to receive placebo. At week 8, the IBDQ had increased ≥16 points over baseline in 5 of 
the tacrolimus and 2 of the placebo patients (45% vs. 20%; p=0.36). Finally, the partial Mayo score 
was reduced by ≥3 points in 8 of the patients receiving rectal tacrolimus compared with 1  patient 
taking placebo (73% vs. 10%; p=0.0037).  The average partial Mayo score at each visit is shown in 
Figure 3. At week 0 the scores were similar (6.3±0.4 vs. 6.9±0.3; p=0.21) in both groups but was 
noted to be numerically lower in the tacrolimus-treated group compared to placebo at week 2 
(4.3±0.74 vs. 5.8±0.64; p=0.15) and week 4 (3.7±0.96 vs. 5.8±0.6; p=0.08) but was significantly 
lower at week 8 (3.3±1.2 vs. 6.7±0.62; p=0.01). 
 
Tacrolimus Trough Levels and safety 
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No important differences were observed among the study groups. There was no correlation between 
the tacrolimus trough levels and clinical outcomes and there was also no correlation between the 
trough levels and side effects. There were no serious infections and no hospitalisations. No cases of 
anaphylaxis or serum sickness were observed. One patient in the placebo arm withdrew from the 
study at week 6 due to pregnancy without improvement in the colitis symptoms. In consultation 
with the patient’s obstetrician and fetal specialist she was treated with open-label rectal tacrolimus 
with resolution of her proctitic symptoms. The baby was born at term without any complications. In 
the placebo arm, there was one episode of a throat infection requiring antibiotics and one patient 
complained of burning feet and aching wrists.   
 
Patients were asked to delay administering their rectal preparation until they had had their trough 
level blood tests taken. The average tacrolimus trough level at week 2 was 6.5±2.2ug/L, 
4.2±1.6ug/L at week 4 and 5.2±2.2ug/L at week 8 (therapeutic range 5-20ug/L). Tacrolimus trough 
levels, however, varied from undetectable to as high as 23.2ug/L. Four of the 11 tacrolimus-treated 
patients had trough levels >10ug/L and it was noted that the blood draw in these patients was later 
in the day ranging from 11.45am to 3.20pm. If patients had already taken the rectal preparation in 
the morning prior to the trough level these would not be true trough levels. With the exclusion of 
these anomalous levels the average tacrolimus trough level at each time point was subtherapeutic 
(<5ug/L). 
  
In the tacrolimus treatment arm, one patient suffered an upper respiratory tract infection that 
resolved spontaneously without treatment (tacrolimus trough level undetectable weeks 2, 4 and 8). 
One patient noted a mild tremor that did not affect normal activity (tacrolimus trough level 
undetectable weeks 2, 4 and 8). Another patient suffered self-limiting dizziness within the first 2 
weeks of the study. This patient also had a mild elevation in the urea 10.6mmol/L (normal range 
2.9-8.2mmol/L) at inclusion to the study that did not rise with tacrolimus treatment (tacrolimus 
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trough level 5.1ug/L at week 2 and then undetectable weeks 4 and 8). At no point was there a rise in 
the creatinine and the glomerular filtration rate did not drop over the treatment period. A final 
patient complained of a headache that resolved with paracetamol (tacrolimus trough level average 
11ug/L with the collection times 1.13pm and 12.45pm despite confirmation by the patient diary of 
administration of the morning rectal tacrolimus dose suggesting that this was not a true trough 
level). There were two further patients with tacrolimus trough levels >10ug/L at some stage in the 
study (maximum level of 23.2ug/L with a collection time of 2.14pm and 12.6ug/L with a collection 
time 12.55) who did not suffer any adverse effects.  
 
Of note was that there were no cases of hyperglycemia, a rise in the serum creatinine, or a drop in 
the glomerular filtration rate suggesting no nephrotoxicity in any patient with the use of tacrolimus. 
No episodes of paresthesia, hypertension, insomnia or nausea were reported.  
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DISCUSSION 
This paper identifies an effective new therapy for the induction of response, and remission, in 
patients with active distal UC that is resistant to topical and oral therapies.  Due to the efficacy of 
this treatment recruitment in the study was terminated early following the interim analysis as the 
analysis demonstrated a significant effect of treatment with rectal tacrolimus over placebo across 
multiple assessments. With enrollment of half of the number of patients predicted to be required to 
show a significant difference, this trial demonstrated that rectal tacrolimus was effective in inducing 
a clinical response and remission for colitis limited to 25cm from the anal verge and resistant to the 
conventional therapies of either oral and/or rectal 5-aminosalicylates (5ASAs) and/or oral and rectal 
steroids. The primary endpoint of a clinical response at 8 weeks was achieved. The secondary 
endpoints of clinical remission, mucosal healing and a partial Mayo score response were also 
achieved while numerically more patients had an improvement in the IBDQ in the treatment, over 
the placebo, arm but this did not reach clinical significance. Longitudinal assessment of the partial 
Mayo score also demonstrated a treatment benefit.  
 
Toxicity and adverse effects of oral tacrolimus is related to the serum trough levels. Despite the fact 
that tacrolimus is readily absorbed through the dermis and thus also the rectal mucosa, the trough 
levels in our patients were generally low and so it is not surprising that the number of adverse 
events was also low. The trough levels in some patients, however, were high yet this did not 
correlate to any adverse outcomes and may have been secondary to the administration of the rectal 
preparation prior to the trough blood collection resulting in a peak, rather than trough, tacrolimus 
blood level.  
 
One patient on the rectal tacrolimus, however, did note the presence of a fine tremor that is a well 
recognized side effect of tacrolimus therapy. There were, however, no adverse effects of renal 
dysfunction, hyperglycemia,, paresthesia, hypertension, insomnia or nausea reported. There were no 
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cases of serious infection and no serious adverse events in either arm. There was one pregnancy in a 
patient in the placebo arm who withdrew from the study at week 6. Longer-term epidemiologic 
studies and clinical experience, however, are still required to more fully determine the risk of 
adverse events from the use of rectal tacrolimus. 
 
The study does have some important limitations. This is an induction study only and it is yet to be 
proven that the use of rectal tacrolimus is effective, or safe, for long-term use. The dose selected for 
the study was 0.5mg/ml administered as 3ml twice a day.  Our initial paper, and further experience, 
has demonstrated that higher concentrations of 0.8mg/ml or 1.0mg/ml tacrolimus in the rectal cream 
may be effective in patients who do not respond to 0.5mg/ml. Superiority of these concentrations 
over the doses in this study, however, have yet to be formally studied, but could offer greater 
efficacy. Finally, the numbers in this study are small but the level of clinical efficacy and mucosal 
healing in the treatment arm were highly significant, despite the small numbers, prompting the early 
closure of the study. Due to the efficacy of the medication further work is planned to be undertaken 
in resistant pouchitis and perianal Crohn’s disease. Long-term use of the rectal medication is also 
going to be assessed for safety, efficacy, ability of de-escalation and withdrawal of the tacrolimus 
medication and the need for reintroduction of the medication. 
 
In conclusion, rectal tacrolimus is effective for the induction of response, and remission, for patients 
with active distal UC that has been resistant to topical and oral therapies. 
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Figure Legends 
 
Figure 1: Primary and secondary endpoints at Week 8 
 
Figure 2: Mayo score at Weeks 0 and 8 
 
Figure 3: Mean Partial Mayo score 
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Placebo 
n=10 
Tacrolimus 
n=11 P-Value 
Age (yrs) 39.0±4.8 48.4±4.9 NS 
Male sex; no. (%) 4 (40%) 8 (73%) NS 
Age at Diagnosis: 
A1 - ≤16 
A2 - 17-40 
A3 - >40 
 
 0 (%) 
8 (80%) 
2 (20%) 
 
 0 (%) 
5 (44%) 
6 (56%) 
 
  
NS 
Disease duration; yr ± SEM 7.2 ± 1.3 9.2 ± 1.9 NS 
Family History IBD; no. (%) 2 (20%) 2 (18%) NS 
Smoking; no. (%) 
    Never 
    Ex-smoker 
    Current 
 
2 (20%) 
8 (80%) 
0 (%) 
 
2 (18%) 
9 (82%) 
0 (%) 
 
 
NS 
 
EIM; no. (%) 
    None 
    Joints (Arthritis / arthralgia) 
    Eyes (Iritis / episcleritis etc) 
    Skin (EN, PG) 
    PSC 
 
8 (80%) 
2 (20%) 
0 (0%) 
0 (0%) 
0 (0%) 
 
8 (73%) 
3 (27%) 
1 (9%) 
0 (0%) 
0 (0%) 
 
NS 
NS 
NS 
Mayo Score (±SEM) 
Mayo Endoscopy Subscore 
         3 
         2 
Partial Mayo Score (±SEM) 
IBDQ Score (±SEM) 
9.6±0.5 
 
4 (40%) 
6 (60%) 
7.1±0.4 
160±9 
8.6±0.4 
 
6 (55%) 
5 (45%) 
6.3±0.4 
141±6 
NS  
 
NS 
NS 
NS 
NS 
Concomitant Medications for UC; no. (%) 
5-aminosalysylic acids 
    Oral/topical 
Gluocorticoids 
    Oral 
    Topical 
Immunosuppressants 
    AZA/6MP 
    MTX 
 
Anti-TNF alpha 
 
 
8 (80%) 
 
3 (30%) 
2 (20%) 
 
5 (50%) 
0 (0%) 
 
0 (0%) 
 
 
8 (72%) 
 
2 (18%) 
4 (36%) 
 
5 (44%) 
1 (9%) 
 
0 (0%) 
 
 
NS 
 
NS 
NS 
 
NS 
NS 
 
NS 
 
Table 1: Demographic and Baseline Characteristics with Concomitant Medications 
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 Placebo (n=10) Tacrolimus (n=11) P-Value 
Clinical Response 1 (10%) 8 (73%) 0.0037 
Clinical Remission 0 (0%) 5 (45%) 0.015 
Mucosal Healing 1 (10%) 8 (73%) 0.0037 
Change in IBDQ 2 (20%) 5 (45%) 0.36 
Partial Mayo response 1 (10%) 8 (73%) 0.0037 
 
Table 2: Outcome Measures at Week 8  
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Figure 1: Primary and secondary endpoints at Week 8 
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Figure 2: Mayo score at Weeks 0 and 8 
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Figure 3: Mean Partial Mayo score 
 
 
 
 
